LifeRxMD must disclose compounded drugs are not FDA-approved under Novo Nordisk settlement
One compounding pharmacy's marketing must now say plainly that its products are not FDA-approved, a reminder that compounded semaglutide is not the same as Ozempic, Wegovy or Rybelsus.
A permanent injunction now limits how the compounding pharmacy LifeRxMD Inc. can promote its products, closing a false-advertising fight Novo Nordisk brought more than two years ago [1][2].
The final judgment is dated Sept. 2 and was entered in the U.S. District Court for the District of New Jersey, where Judge Michael A. Shipp handled the matter [1][2]. The two sides settled the case, and the settlement terms are confidential [2]. Bloomberg Law described the agreement as resolving a pending two-year advertising challenge [1].
Novo Nordisk had argued that LifeRxMD's promotions implied its compounded medicines were genuine, cleared or examined by the FDA, or tied to — or interchangeable with — the brand-name drugs Novo Nordisk makes [2]. The pharmacy denied those allegations [2].
The injunction concerns promotional statements about Ozempic, Wegovy and Rybelsus, all brand names for semaglutide [2].
What the order requires
The injunction has two main parts. LifeRxMD may not use Novo Nordisk's trademarks in particular ways while advertising or selling compounded drugs [2]. And for a year, the company must state that the compounded drugs it offers have not been approved or reviewed by the FDA for safety, effectiveness or quality, and that FDA-approved semaglutide products exist [2]. Bloomberg Law reported that the required notice must appear "conspicuously and prominently" in the pharmacy's marketing [1].
Whether LifeRxMD still sells compounded semaglutide has not been reported, and the date the 12-month disclosure period began has not been disclosed [2].
Why it matters for patients
Compounded medications do not go through FDA approval, and the agency does not check them for safety, effectiveness or quality before they reach buyers [2]. A compounded semaglutide product is therefore not Ozempic, Wegovy or Rybelsus, no matter how closely a seller's wording links the two.
For anyone comparing a compounded option with a brand-name prescription, this order changes one seller's advertising rather than the products themselves [1][2]. The disclosures it requires are the kind of plain statement — this has not been FDA-approved — that can help a reader spot the difference when a listing or ad blurs it [2].
The reach is narrow. The case involved one pharmacy's marketing, so it does not show how other compounders describe what they sell [2]. It also does not alter the legal status of any compounded drug or give one FDA approval; the order governs advertising claims only [2].
What happens next
LifeRxMD's disclosure duty runs for 12 months under the injunction, with no reported start date [2].
Separately, Eli Lilly sued six companies in August over allegations they sold its investigational drug retatrutide, which is not approved, and the company has referred more than 200 entities to federal and state authorities [2]. That matter is unrelated to the LifeRxMD settlement and remains open [2].
Novo Nordisk's patent dispute with Hims & Hers over a compounded Wegovy pill, filed in February, ended in a partnership the following month instead of continuing in court [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.